Published on www.emcdda.europa.eu (http://www.emcdda.europa.eu)

Home > Countries > > Public expenditure in Denmark 2018

Countries

Austria [1]
Belgium [2]
Bulgaria [3]
Croatia [4]
Cyprus [5]
Czechia [6]
Denmark [7]
Estonia [8]
Finland [9]
France [10]
Germany [11]
Greece [12]
Hungary [13]
Ireland [14]
Italy [15]
Latvia [16]
Lithuania [17]
Luxembourg [18]
Malta [19]
Netherlands [20]
Norway [21]
Poland [22]
Portugal [23]
Romania [24]
Slovakia [25]
Slovenia [26]
Spain [27]
Sweden [28]
Turkey [29]
United-Kingdom [30]

[7] Denmark Country Drug Report 2018

Denmark main page [7] Sections 
National drug strategy and coordination [31]

What are the long-term aims of drug policy in Denmark? How are these aims to be achieved? How is drug policy coordinated at national level?

 Learn more [31]
Public expenditure [32]

Understanding the costs of drug-related actions is an important aspect of policy evaluation.

 Learn more [32]
Drug laws and drug law offences [33]

What substances and activities does Denmark control under its drug laws? What are the penalties for offences? How are new psychoactive substances controlled?

 Learn more [33]
Drug use [34]

How many people in Denmark have ever used drugs? What drugs have they used? How many have used drugs recently? How many are using drugs in highly risky ways?

 Learn more [34]
Drug harms [35]

What are the main infectious diseases linked to drug injecting in Denmark? How many died of drug overdose in the last year? How many drug-related medical emergencies occurred?

 Learn more [35]
Prevention [36]

What part does prevention play in Denmark drug strategy. What are the main prevention approaches used in the country and who do they target?

 Learn more [36]
Harm reduction [37]

How does the Denmark measure in terms of provision of needle and syringe programmes, peer naloxone programmes, supervised drug consumption rooms and heroin-assisted treatment.

 Learn more [37]
Treatment [38]

How is the drug treatment system organised in Denmark? How is it financed? How is the provision of treatment divided between inpatient and outpatient settings?

 Learn more [38]
Drug use and responses in prison [39]

Which authorities are responsible for prison health in Denmark? What forms of drug treatment and harm reduction are provided in prisons, and how widely?

 Learn more [39]
Quality assurance [40]

What is done in Denmark to ensure that the prevention and treatment interventions used are effective and provide a good return on public expenditure?

 Learn more [40]
Drug-related research [41]

In which areas of study is drug-related research carried out in Denmark? How is this research funded? Are any types of research emphasised in the national drug strategy?

 Learn more [41]
Drug markets [42]

What is known about drug supply and trafficking in Denmark? How pure or strong are the drugs available? What do they cost? What are the main aims of supply reduction efforts?

 Learn more [42]
Key statistics [43]

Key drug statistics for Denmark

 Learn more [43]
EU Dashboard [44]

Focus on Denmark

 Learn more [44]

Public expenditure

Understanding of the costs of drug-related actions is an important aspect of drug policy. Some of the funds allocated by governments for expenditure on tasks related to drugs are identified as such in the budget (‘labelled’). Often, however, most drug-related expenditure is not identified (‘unlabelled’) and must be estimated using modelling approaches.

In Denmark, multiannual drug budgets are associated with a number of interventions in the field of drugs under the Social Reserve Grants Agreement. Available data on drug-related public expenditure are multiannual and include only labelled expenditure. Reported data show that the Social Reserve Grants Agreement had a planned budget of EUR 19.5 million for drug-related initiatives between 2004 and 2007. In 2006, this budget was reinforced, reaching EUR 33.6 million over the period 2006-09. In 2008 and 2009, this budget was provided with an additional EUR 16.4 million and, in 2011, received EUR 9.6 million more. In 2012, a total of EUR 3.2 million was budgeted for 2012-15. Later, for the period 2013-18, a budget of EUR 13.8 million was assigned to central government. In 2015, several treatment and social reintegration programmes were launched (e.g. EUR 4.7 million to co-finance drug consumption rooms; EUR 9.2 million to support programmes for anonymous treatment of drug users; EUR 1 million for naloxone programmes; EUR 1.2 million for interventions reaching young people with cannabis-related psychosis; and EUR 0.4 million for prevention programmes among students). In 2016, the treatment of drug users in prison had a budget of EUR 15 million, which represented an increase on previous years.

The data available for local government expenditure indicate that EUR 120.9 million and EUR 124 million were spent on drug treatment in 2014 and 2015, respectively. As regards social treatment, a slight increase was registered between 2013 and 2016; in 2016, spending reached EUR 129 million (DKK 961 million), compared with EUR 126 million (DKK 942 million) in 2015, at 2017 prices. However, no data are available for municipal expenditure on prevention and medical treatment.


Denmark main page [7]
Source URL: http://www.emcdda.europa.eu/countries/drug-reports/2018/denmark/public-expenditure_en

Links
[1] http://www.emcdda.europa.eu/countries/drug-reports/2018/austria_en
[2] http://www.emcdda.europa.eu/countries/drug-reports/2018/belgium_en
[3] http://www.emcdda.europa.eu/countries/drug-reports/2018/bulgaria_en
[4] http://www.emcdda.europa.eu/countries/drug-reports/2018/croatia_en
[5] http://www.emcdda.europa.eu/countries/drug-reports/2018/cyprus_en
[6] http://www.emcdda.europa.eu/countries/drug-reports/2018/czech-republic_en
[7] http://www.emcdda.europa.eu/countries/drug-reports/2018/denmark_en
[8] http://www.emcdda.europa.eu/countries/drug-reports/2018/estonia_en
[9] http://www.emcdda.europa.eu/countries/drug-reports/2018/finland_en
[10] http://www.emcdda.europa.eu/countries/drug-reports/2018/france_en
[11] http://www.emcdda.europa.eu/countries/drug-reports/2018/germany_en
[12] http://www.emcdda.europa.eu/countries/drug-reports/2018/greece_en
[13] http://www.emcdda.europa.eu/countries/drug-reports/2018/hungary_en
[14] http://www.emcdda.europa.eu/countries/drug-reports/2018/ireland_en
[15] http://www.emcdda.europa.eu/countries/drug-reports/2018/italy_en
[16] http://www.emcdda.europa.eu/countries/drug-reports/2018/latvia_en
[17] http://www.emcdda.europa.eu/countries/drug-reports/2018/lithuania_en
[18] http://www.emcdda.europa.eu/countries/drug-reports/2018/luxembourg_en
[19] http://www.emcdda.europa.eu/countries/drug-reports/2018/malta_en
[20] http://www.emcdda.europa.eu/countries/drug-reports/2018/netherlands_en
[21] http://www.emcdda.europa.eu/countries/drug-reports/2018/norway_en
[22] http://www.emcdda.europa.eu/countries/drug-reports/2018/poland_en
[23] http://www.emcdda.europa.eu/countries/drug-reports/2018/portugal_en
[24] http://www.emcdda.europa.eu/countries/drug-reports/2018/romania_en
[25] http://www.emcdda.europa.eu/countries/drug-reports/2018/slovakia_en
[26] http://www.emcdda.europa.eu/countries/drug-reports/2018/slovenia_en
[27] http://www.emcdda.europa.eu/countries/drug-reports/2018/spain_en
[28] http://www.emcdda.europa.eu/countries/drug-reports/2018/sweden_en
[29] http://www.emcdda.europa.eu/countries/drug-reports/2018/turkey_en
[30] http://www.emcdda.europa.eu/countries/drug-reports/2018/united-kingdom_en
[31] http://www.emcdda.europa.eu/countries/drug-reports/2018/denmark/national-drug-strategy-and-coordination_en
[32] http://www.emcdda.europa.eu/countries/drug-reports/2018/denmark/public-expenditure_en
[33] http://www.emcdda.europa.eu/countries/drug-reports/2018/denmark/drug-laws-and-drug-law-offences_en
[34] http://www.emcdda.europa.eu/countries/drug-reports/2018/denmark/drug-use_en
[35] http://www.emcdda.europa.eu/countries/drug-reports/2018/denmark/drug-harms_en
[36] http://www.emcdda.europa.eu/countries/drug-reports/2018/denmark/prevention_en
[37] http://www.emcdda.europa.eu/countries/drug-reports/2018/denmark/harm-reduction_en
[38] http://www.emcdda.europa.eu/countries/drug-reports/2018/denmark/treatment_en
[39] http://www.emcdda.europa.eu/countries/drug-reports/2018/denmark/drug-use-and-responses-prison_en
[40] http://www.emcdda.europa.eu/countries/drug-reports/2018/denmark/quality-assurance_en
[41] http://www.emcdda.europa.eu/countries/drug-reports/2018/denmark/drug-related-research_en
[42] http://www.emcdda.europa.eu/countries/drug-reports/2018/denmark/drug-markets_en
[43] http://www.emcdda.europa.eu/countries/drug-reports/2018/denmark/key-statistics_en
[44] http://www.emcdda.europa.eu/countries/drug-reports/2018/denmark/eu-dashboard_en